Back to results
US 8,709,715 B2Granted
Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
AssigneeCellerant Therapeutics, Inc.
InventorHolger Karsunky
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
Claims6
A method of monitoring the efficacy of treating acute myelogenous leukemia (AML) in a patient, comprising
- obtaining a test sample from said patient at two or more time points during said treatment of AML, wherein the test sample is a blood sample
- detecting a level of an expression product corresponding to interleukin 1 receptor accessory protein (IL1RAP) in CD34+ cells in each of the test samples, and
- determining that the patient has a positive response to treatment of AML when the level in the levels of said expression product are reduced over time.
Dependencies are inferred from the claim text.